1. Home
  2. FORR vs INDP Comparison

FORR vs INDP Comparison

Compare FORR & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Forrester Research Inc.

FORR

Forrester Research Inc.

N/A

Current Price

$12.11

Market Cap

135.7M

ML Signal

N/A

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

N/A

Current Price

$1.60

Market Cap

125.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FORR
INDP
Founded
1983
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
135.7M
125.2M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
FORR
INDP
Price
$12.11
$1.60
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
79.0K
844.5K
Earning Date
05-06-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.25
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.88
$0.92
52 Week High
$12.75
$8.57

Technical Indicators

Market Signals
Indicator
FORR
INDP
Relative Strength Index (RSI) 60.74 47.88
Support Level $11.04 $0.92
Resistance Level $12.33 $1.58
Average True Range (ATR) 0.42 0.15
MACD -0.03 0.06
Stochastic Oscillator 69.50 55.57

Price Performance

Historical Comparison
FORR
INDP

About FORR Forrester Research Inc.

Forrester Research Inc provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

Share on Social Networks: